Tradestie Institutional Equity Comparison Engine

LCTX vs DNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DNA Overall Edge

DNA Captures Institutional Edge (3โ€“1 Pillars ยท 4โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ginkgo Bioworks Holdings, Inc. (DNA) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while LCTX counters with relative strength in Valuation. Fundamentally, LCTX trades at 30.7x Forward P/E with -280.3% operating margin (-61.0% YoY revenue) versus DNA at N/M Forward P/E and -202.5% operating margin (-5.7% YoY). In options structure, LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro) against DNA sits in BREAKDOWN (24th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
LCTX 30.7x vs DNA N/M Fwd P/E
Growth & Margin Winner DNA
Op Margin -280.3% vs -202.5% ยท YoY -61.0% vs -5.7%
Momentum & Technical Winner DNA
1Y -53.7% vs +4.7% ยท 52W Pos 4% vs 22%
Options & Structure Winner DNA
BREAKDOWN (100th %ile IV) vs BREAKDOWN (24th %ile IV)
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.20
-2.84% 1D
Market Cap $547.1M
1M Return -18.08%
1Y Return +4.73%
Forward P/E N/M
Unified AI Score
58.4 / 100 HOLD
Tech 40.0 Fund 53.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LCTX -53.67% DNA +4.73% Spread: +58.4 pp (DNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LCTX Revenue DNA Revenue LCTX Op. Margin DNA Op. Margin Margin Edge
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M $50M -1106.0% -132.1% DNA
FY2020 $0M $80M -1448.4% -178.8% DNA
FY2021 $0M $310M -1133.6% -582.6% DNA
FY2022 $10M $480M -153.2% -462.4% LCTX
FY2023 $10M $250M -276.5% -343.8% LCTX
FY2024 $10M $230M -226.1% -246.5% LCTX
FY2025 $10M $170M -251.6% -185.3% DNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LCTX (6) vs DNA (4)
Institutional Metric LCTX DNA Criterion Row Winner
Market Capitalization Scale $212.1M $547.1M Larger Scale DNA
Trailing P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Forward P/E Ratio Valuation 30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY) Growth -61.0% -5.7% Higher Growth DNA
Operating Margin (TTM) Profitability -280.3% -202.5% Higher Margin DNA
Net Profit Margin Profitability 16.2% -192.0% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency 4.3% -58.2% Higher ROE LCTX
52-Week Range Position Momentum 4% ($1โ€“$2) 22% ($5โ€“$18) Stronger Trend DNA
Beta / 30D Volatility Risk Regime 1.36ฮฒ ยท 79% Vol 3.12ฮฒ ยท 149% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 58.9 / 100 (HOLD) 58.4 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LCTX vs DNA Buy Guide
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DNA BREAKDOWN
33d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live DNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LCTX nor DNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.